Pharmaceutical Distribution Scale and Specialty Oncology Expansion

McKesson Corporation is one of the largest pharmaceutical distributors in the world, operating primarily through two segments: U.S. Pharmaceutical and Prescription Technology Solutions, alongside international operations. The company purchases drugs directly from manufacturers and distributes them to retail pharmacies, hospitals, health systems, and clinics.

How it makes money: McKesson earns a distribution margin — a spread between the purchase price and the sale price — plus fees for value-added services. Because gross margins are thin (typically low single digits), profitability depends on volume, purchasing scale, and working-capital efficiency.

Customers: Large retail pharmacy chains, independent pharmacies, hospitals, health systems, and government healthcare programs. The oncology network serves thousands of community-based providers.

Scale: With a $104.1B market cap and $37.27 in EPS, McKesson operates one of the most extensive distribution footprints in North America, handling enormous daily unit volumes that create significant barriers to entry.

Near-term (1-2 years): Growth is driven by (1) branded drug price inflation, which mechanically lifts revenue, (2) generic drug volume growth as patent cliffs expand the generic pool, and (3) continued specialty pharmaceutical penetration. These factors support low-to-mid single-digit revenue growth with modest margin expansion.

Medium-term (3-5 years): The specialty and oncology platforms are the key levers. As biologics and specialty therapies grow as a share of total pharmaceutical spend, McKesson's higher-margin services become a larger portion of the mix. Prescription technology solutions — including prior authorization and patient support — offer software-like margins that can lift consolidated profitability.

The narrative: revenue growth is modest but reliable, driven by drug price inflation and volume. The real earnings driver is mix — specialty and technology solutions lift margins, while buybacks reduce the share count. Together these produce EPS growth that outpaces revenue growth, the central financial story for McKesson.

Market size/TAM: The global pharmaceutical distribution market is measured in the hundreds of billions of dollars, with the U.S. representing the largest single market. Specialty pharmaceuticals are the fastest-growing sub-segment.

Competitive positioning: McKesson is one of three dominant U.S. distributors, alongside Cencora (COR) and Cardinal Health (CAH). Scale, purchasing power, and logistics infrastructure are the primary competitive weapons. McKesson's oncology and technology assets differentiate it from pure-play distributors.

Comparable companies:

• Cencora (COR) — Direct competitor in U.S. and international distribution.
• Cardinal Health (CAH) — Competitor in pharmaceutical and medical distribution.
• AmerisourceBergen (legacy, now part of Cencora) — Historical peer.
• Henry Schein (HSIC) — Adjacent medical/specialty distribution comparable.

DCF discussion: A discounted cash flow analysis for McKesson centers on stable free cash flow generation, a low cost of equity (supported by the 0.31 beta), and modest terminal growth. Given the defensive cash flows, the DCF is sensitive to the discount rate assumption; a low-beta, non-cyclical profile justifies a lower required return, supporting a higher present value. The key value driver is the durability of cash flows and the compounding effect of buybacks.

Comparable multiples:

At approximately 24.1x trailing EPS ($898.52 / $37.27), McKesson trades at a premium to distribution peers, reflecting its specialty and oncology mix and superior capital return. We view the premium as justified provided specialty growth continues.

• Customer concentration: A significant portion of revenue derives from large retail pharmacy customers; loss or renegotiation of a major contract could pressure margins.
• Drug pricing and reimbursement policy: Legislative changes to drug pricing, reimbursement rates, or the generic/branded mix could compress distribution spreads.
• Generic deflation: While volume grows, generic price deflation can pressure gross margin if not offset by mix.
• Opioid-related litigation: Legacy litigation exposure remains an overhang for the sector, with potential settlement costs.
• Macro and interest-rate sensitivity: Working-capital-intensive operations are sensitive to interest rates and inventory financing costs.